Subscribe To
POAI / Predictive Oncology Inc. (POAI) Upgraded to Buy: What Does It Mean for the Stock?
POAI News
By Seeking Alpha
August 10, 2023
Predictive Oncology, Inc. (POAI) Q2 2023 Earnings Call Transcript
Predictive Oncology, Inc. (NASDAQ:POAI ) Q2 2023 Earnings Conference Call August 10, 2023 5:30 PM ET Company Participants Glenn Garmont - Managing Dir more_horizontal
By Proactive Investors
August 10, 2023
Predictive Oncology dramatically narrows its quarterly loss in latest financial results
Predictive Oncology reported its second-quarter financial results after the bell Thursday, including a significantly narrower loss than the same quart more_horizontal
By Proactive Investors
July 18, 2023
Predictive Oncology moves company headquarters to Pittsburgh
Predictive Oncology Inc. (NASDAQ:POAI) announced that it has moved its corporate headquarters to its main laboratory facility in Pittsburgh, Pennsylva more_horizontal
By Proactive Investors
June 27, 2023
Predictive Oncology adds biopharmaceutical CFO Andrew Einhorn to business advisory board
Predictive Oncology Inc. (NASDAQ:POAI) has announced the addition of biopharmaceutical finance industry veteran Andrew Einhorn to its business advisor more_horizontal
By Proactive Investors
June 20, 2023
Predictive Oncology appoints Dr Bernard Harris Jr to Business Advisory Board
Predictive Oncology Inc. (NASDAQ:POAI) has announced the appointment of Dr Bernard Harris Jr to its newly-formed Business Advisory Board (BAB). The more_horizontal
By Proactive Investors
May 16, 2023
Predictive Oncology forges key partnerships to drive oncology drug development in 1Q
Predictive Oncology has updated investors on its use of artificial intelligence (AI) and machine learning and its extensive biorepository of tumor s more_horizontal
By Seeking Alpha
May 15, 2023
Predictive Oncology, Inc. (POAI) Q1 2023 Earnings Conference Call Transcript
Predictive Oncology, Inc. (NASDAQ:POAI ) Q1 2023 Earnings Conference Call May 15, 2023 5:30 PM ET Company Participants Glenn Garmont - Managing Direct more_horizontal
By Proactive Investors
April 4, 2023
Predictive Oncology appoints translational research leader Christoph Reinhard to scientific advisory board
Predictive Oncology Inc. (NASDAQ:POAI) announced the appointment of Dr. Christoph Reinhard to its scientific board to serve alongside other key though more_horizontal